Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan Versus Pantoprazole for Acute Non-Variceal Upper Gastrointestinal Bleeding
NCT07776730Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Randomised trial of keverprazan in non-variceal upper gastrointestinal bleeding (NVUGIB) (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Incidence of rebleeding at 14 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
keverprazan
03
Conditions
non-variceal upper gastrointestinal bleeding (NVUGIB)
Beyond the preview
Go deeper on NCT07776730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776730.